ISRCTN81436702 https://doi.org/10.1186/ISRCTN81436702

Phase 1 Trial: RD 792.34234 (SPON1896-22)

Submission date 23/01/2023	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 24/01/2023	**Overall study status** Deferred	[ ] Statistical analysis plan [ ] Results
Last Edited 24/01/2023	**Condition category** Other	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Scientific

Contact name
Mrs MDI Neuroscience Portfolio Manager

Contact details
Cardiff University
Medicines Discovery Institute
Main Building
Park Place
Cardiff
United Kingdom
CF10 3AT
+ 44 (0)2922 511 095
swettenhamj@cardiff.ac.uk

Type(s)
Public

Contact name
Mrs MDI Neuroscience Portfolio Manager

Contact details
Cardiff University
Medicines Discovery Institute
Main Building

Park Place
Cardiff
United Kingdom
CF10 3AT
+ 44 (0)2922 511 095
swettenhamj@cardiff.ac.uk

Type(s)
Principal investigator

Contact name
Dr Annelize Koch

Contact details
Simbec-Orion Clinical Pharmacology
Merthyr Tydfil Industrial Park
Cardiff Road
Merthyr Tydfil
United Kingdom
CF48 4DR
+44 (0)1443694313
annelize.koch@simbecorion.com

Additional identifiers

Clinical Trials Information System (CTIS)
2022-002562-33

Integrated Research Application System (IRAS)
1006242

Protocol serial number
SPON1896-22

Study information

Scientific Title
Phase 1 Trial: RD 792.34234 (SPON1896-22) [The full scientific title will be published within 30 months after the end of the trial]

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Old ethics approval format

Ethics approval(s)

1. Approved 06/12/2022, Wales Research Ethics Committee 1 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, UK; +44 (0)2920 230457; Wales.REC1@wales.nhs.uk), ref: 22/WA/0320
2. Approved 22/12/2022, MHRA (10 South Colonnade, Canary Wharf, London, E14 4PU, UK; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 21323/0056/001-0001

The HRA has approved deferral of publication of trial details.

Primary study design
Interventional

Study design
A three-part first-in-human trial in up to 116 healthy participants

Study type(s)
Other

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
03/11/2023

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
09/01/2023

Date of final enrolment
29/09/2023

Locations

Countries of recruitment
United Kingdom

Wales

Study participating centre
Simbec Research Limited
Simbec House Merthyr Tydfil Industrial Park
Merthyr Tydfil Industrial Park
Pentrebach
Merthyr Tydfil
Mid Glamorgan
United Kingdom
CF48 4DR

Sponsor information

Organisation
Cardiff University

ROR
https://ror.org/03kk7td41

Funder(s)

Funder type
Charity

Funder Name
Wellcome Trust

Alternative Name(s)
Wellcome, WT

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary
Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No